Skip to Content


Lisa Ouellette
Written Description Blog
July 27, 2015

Read the Full Article

From the review:

I highly recommend two recently posted articles on declining innovation incentives for diagnostic tests, particularly due to changes in patentable subject matter doctrine. In Innovation Law and Policy: Preserving the Future of Personalized Medicine, Rachel Sachs (Petrie-Flom Fellow at Harvard Law) examines the intersection of IP with FDA regulation and health law, joining a growing body of scholarship that seeks to contextualize IP in a broader economic context.

Read the Full Article

Tags

fda   health law policy   innovation   intellectual property   rachel sachs   regulation